Evidence map›Paper›PMID 20980437›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2010

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Vicki Gordon, Shriti Bhadel, Winfried Wunderlich, JoAnn Zhang, Scott B Ficarro, Sahana A Mollah, Jeffrey Shabanowitz, Donald F Hunt, Ioannis Xenarios, William C Hahn and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 134 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Targeting transcription cycles in cancer.Nature reviews. Cancer · 2022
    Review
  19. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.Journal of enzyme inhibition and medicinal chemistry · 2021
    Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Vicki GordonUniversity of Virginia, Department of Microbiology, Charlottesville, Virginia 22908, USA.
Shriti Bhadel
Winfried Wunderlich
JoAnn Zhang
Scott B Ficarro
Sahana A Mollah
Jeffrey Shabanowitz
Donald F Hunt
Ioannis Xenarios
William C Hahn
Mark Conaway
Michael F Carey
Daniel Gioeli
University of California, Los Angeles · USCharlottesville Medical Research · USDana-Farber Cancer Institute · USUniversity of Lausanne · CHUniversity of Virginia · US

Funding

PROTEIN SEQUENCING BY TANDEM MASS SPECTROMETRYR01GM037537 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HUNT, DONALD F · 1987 to 2023
$17.8M
Role of Androgen Receptor Phosphorylation in Prostate CancerR01CA124706 · NCI · UNIVERSITY OF VIRGINIA · PI GIOELI, DANIEL G · 2008 to 2012
$1.6M
NCI NIH HHS R01 CA124706NIGMS NIH HHS GM 37537NIGMS NIH HHS R01 GM037537
6 · The paper itself

Abstract

Previously we determined that S81 is the highest stoichiometric phosphorylation on the androgen receptor (AR) in response to hormone. To explore the role of this phosphorylation on growth, we stably expressed wild-type and S81A mutant AR in LHS and LAPC4 cells. The cells with increased wild-type AR expression grow faster compared with parental cells and S81A mutant-expressing cells, indicating that loss of S81 phosphorylation limits cell growth. To explore how S81 regulates cell growth, we tested whether S81 phosphorylation regulates AR transcriptional activity. LHS cells stably expressing wild-type and S81A mutant AR showed differences in the regulation of endogenous AR target genes, suggesting that S81 phosphorylation regulates promoter selectivity. We next sought to identify the S81 kinase using ion trap mass spectrometry to analyze AR-associated proteins in immunoprecipitates from cells. We observed cyclin-dependent kinase (CDK)9 association with the AR. CDK9 phosphorylates the AR on S81 in vitro. Phosphorylation is specific to S81 because CDK9 did not phosphorylate the AR on other serine phosphorylation sites. Overexpression of CDK9 with its cognate cyclin, Cyclin T, increased S81 phosphorylation levels in cells. Small interfering RNA knockdown of CDK9 protein levels decreased hormone-induced S81 phosphorylation. Additionally, treatment of LNCaP cells with the CDK9 inhibitors, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole and Flavopiridol, reduced S81 phosphorylation further, suggesting that CDK9 regulates S81 phosphorylation. Pharmacological inhibition of CDK9 also resulted in decreased AR transcription in LNCaP cells. Collectively these results suggest that CDK9 phosphorylation of AR S81 is an important step in regulating AR transcriptional activity and prostate cancer cell growth.

Indexed as

Androgen Receptor AntagonistsAndrogensAnimalsCell Growth ProcessesCells, CulturedChlorocebus aethiopsCOS CellsCyclin-Dependent Kinase 9Cyclin TDichlororibofuranosylbenzimidazoleFlavonoidsGene Knockdown TechniquesHeLa CellsHumansPhosphorylationPiperidinesalvocidibAndrogen Receptor AntagonistsAndrogensCDK9 protein, humanCyclin-Dependent Kinase 9Cyclin TDichlororibofuranosylbenzimidazoleFlavonoidsPiperidinesReceptors, AndrogenRNA, Small InterferingSerineSerine EndopeptidasesTMPRSS2 protein, human

Identifiers

PMID20980437
PMCPMC2999477
OpenAlexW2171020858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.